In vitro activity of TR-700, the antibacterial moiety of the prodrug TR-701, against linezolid-resistant strains.
about
Potential role of tedizolid phosphate in the treatment of acute bacterial skin infectionsResistance to linezolid caused by modifications at its binding site on the ribosomeTargeting Antibiotic ResistanceNew developments in the management of severe skin and deep skin structure infections - focus on tedizolidNewer antibacterial drugs for a new century.Platelet profile in patients with acute bacterial skin and skin structure infections receiving tedizolid or linezolid: findings from the Phase 3 ESTABLISH clinical trials.Tedizolid Phosphate: a Next-Generation Oxazolidinone.Pharmacokinetic drug evaluation of tedizolid for the treatment of skin infections.Postgenomic strategies in antibacterial drug discovery.Waves of resistance: Staphylococcus aureus in the antibiotic era.Probing translation with small-molecule inhibitorsAntibiotics and bacterial resistance in the 21st century.Phase 2, randomized, double-blind, dose-ranging study evaluating the safety, tolerability, population pharmacokinetics, and efficacy of oral torezolid phosphate in patients with complicated skin and skin structure infections.Pharmacokinetics of tedizolid following oral administration: single and multiple dose, effect of food, and comparison of two solid forms of the prodrugTedizolid population pharmacokinetics, exposure response, and target attainment.Tedizolid phosphate.Nonclinical and pharmacokinetic assessments to evaluate the potential of tedizolid and linezolid to affect mitochondrial functionLack of neuropathological changes in rats administered tedizolid phosphate for nine months.Activity of oxazolidinone TR-700 against linezolid-susceptible and -resistant staphylococci and enterococci.In vitro activity of TR-700, the active ingredient of the antibacterial prodrug TR-701, a novel oxazolidinone antibacterial agentTelavancin, a new lipoglycopeptide antimicrobial, in complicated skin and soft tissue infectionsAnalysis of the phase 3 ESTABLISH trials of tedizolid versus linezolid in acute bacterial skin and skin structure infectionsProfile of tedizolid phosphate and its potential in the treatment of acute bacterial skin and skin structure infectionsReversing resistance: The next generation antibacterials.Pulmonary disposition of tedizolid following administration of once-daily oral 200-milligram tedizolid phosphate in healthy adult volunteers.Comparative efficacies of human simulated exposures of tedizolid and linezolid against Staphylococcus aureus in the murine thigh infection model.In vitro activity and microbiological efficacy of tedizolid (TR-700) against Gram-positive clinical isolates from a phase 2 study of oral tedizolid phosphate (TR-701) in patients with complicated skin and skin structure infections.Stability of Crushed Tedizolid Phosphate Tablets for Nasogastric Tube Administration.Comparative pharmacodynamics of the new oxazolidinone tedizolid phosphate and linezolid in a neutropenic murine Staphylococcus aureus pneumonia modelCommunity-associated meticillin-resistant Staphylococcus aureusNew antibiotic agents in the pipeline and how they can help overcome microbial resistance.In vitro, in vivo, and clinical studies of tedizolid to assess the potential for peripheral or central monoamine oxidase interactions.Antibacterial oxazolidinones: emerging structure-toxicity relationships.Linezolid, the first oxazolidinone antibacterial agent.The oxazolidinones: past, present, and future.Tedizolid (TR-701): a new oxazolidinone with enhanced potency.Current and prospective treatments for multidrug-resistant gram-positive infections.Use of pharmacokinetic/pharmacodynamic systems analyses to inform dose selection of tedizolid phosphate.Therapeutic options for vancomycin-resistant enterococcal bacteremia.Tedizolid: a novel oxazolidinone with potent activity against multidrug-resistant gram-positive pathogens.
P2860
Q26853612-62082005-F087-4EF2-90E8-388CEDF1C2FEQ27006772-E3DFF5F8-29D8-4795-86F8-F9E1AC6C3A9CQ28078130-921F3D38-E025-4ABE-B4FF-DD6B479A73D6Q28083116-A913DC3B-2404-44AD-B0F2-8D931BE1CD87Q30433333-B87A8131-866B-4BA5-A9DF-E13253A92DFEQ33417790-94C1FA3A-8B22-45A2-AE13-086CEE808DD8Q33420646-18A51EA1-FB67-4026-9472-0E5D081A6CCAQ33438834-5CE85C75-5A72-4AF0-AD36-634C7C895388Q33745572-61848FBF-BF6A-40E9-9C1E-3A51B69FD019Q33854398-FA1B20AF-704D-42B1-8CEC-D2E1121193CEQ34038634-2CA0D5CF-1B31-42AE-995E-72992168DCF3Q34156349-75CDA660-1C88-433E-BE5D-3B5FDAB8A9D6Q34529205-6B01E14B-2F3A-487C-8CA8-B9118340BAE3Q34548251-786DFAFD-F362-4E7E-9673-5FB866A15864Q34596353-C6244289-F8C9-4ED3-AB21-DA0ECC5770FBQ34612944-5F5E44DF-88DF-47D8-BC99-BDB051FBA3A4Q34922189-636C26EC-8D7F-4034-A889-4CD3E966FFA7Q34922770-AD26F3CA-D43C-49C1-A667-973F7DD824E0Q34928138-8A2C865B-D05D-46B3-9C83-38F58C66AC0EQ34986954-464437CD-CC9B-42BF-8EAE-84B2871BF771Q35026607-193D68E7-DAC2-4845-B37B-E5BCCEEA5E77Q35105971-8EF32F81-FA4A-4EAF-A3E8-2C3ECE6F8DE4Q35542330-577625F4-2895-4282-A505-37D4C9EB8310Q35669688-73CF580E-A5B8-4ED0-A31A-3964CAD0EAE1Q35941279-13BE8F99-0FEF-4F9A-9086-D6BFE56BA426Q36171683-2E0D3C18-A9FF-4387-A072-A19561F1F06FQ36172450-90863EC4-6A79-4697-B683-6A080284B5F8Q36327804-F133B509-C4A0-4911-B147-AAC6A5486D35Q36364009-2F247D4A-55D2-4CD8-A5AC-D6D5C13BAF2CQ36438720-E1F6B9A6-61EF-46C8-9ADC-0300FA9EEB3AQ36845895-E87C2B83-F2E6-420D-ACDA-0D9B9DBAA0B3Q36969769-D6D4894C-768F-472C-BB97-E750932BE831Q37747401-5EC48AC1-2F0E-4E12-8288-BC918DBB6E1FQ37857331-6012DCF2-7E1B-4F9E-AFA5-1AD2E68BEFD1Q37970719-5D9BBAF7-7390-4361-A96B-F855B4F3A70FQ37983130-F7155F33-17F5-46E7-A1A2-16A1BEA2ED61Q38123255-311FDE62-D61C-4B90-9C66-94A9BC3A0D84Q38171760-44ED2797-85CE-4CBF-9878-48AD534A2863Q38347869-B385D45B-0EBF-4384-A99C-BEC47E260015Q38352171-E7E68CF6-762B-4279-8D7B-DD9BFABB3003
P2860
In vitro activity of TR-700, the antibacterial moiety of the prodrug TR-701, against linezolid-resistant strains.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
In vitro activity of TR-700, t ...... t linezolid-resistant strains.
@en
type
label
In vitro activity of TR-700, t ...... t linezolid-resistant strains.
@en
prefLabel
In vitro activity of TR-700, t ...... t linezolid-resistant strains.
@en
P2093
P2860
P356
P1476
In vitro activity of TR-700, t ...... st linezolid-resistant strains
@en
P2093
C M Pillar
D Shinabarger
V Brown-Driver
P2860
P304
P356
10.1128/AAC.00859-08
P407
P50
P577
2008-10-06T00:00:00Z